We are live on ! Find out more
EW icon

Edwards Lifesciences

1,253 hedge funds and large institutions have $38.2B invested in Edwards Lifesciences in 2025 Q3 according to their latest regulatory filings, with 113 funds opening new positions, 444 increasing their positions, 443 reducing their positions, and 106 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more first-time investments, than exits

New positions opened: 113 | Existing positions closed: 106

0% more repeat investments, than reductions

Existing positions increased: 444 | Existing positions reduced: 443

0% more funds holding in top 10

Funds holding in top 10: 1010 (0)

0% less funds holding

Funds holding: 1,2591,253 (-6)

3% less capital invested

Capital invested by funds: $39.4B → $38.2B (-$1.2B)

1.96% less ownership

Funds ownership: 85.71%83.75% (-2%)

13% less call options, than puts

Call options by funds: $295M | Put options by funds: $337M

Holders
1,253
Holders Change
-6
Holders Change %
-0.48%
% of All Funds
16.44%
Holding in Top 10
10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.13%
New
113
Increased
444
Reduced
443
Closed
106
Calls
$295M
Puts
$337M
Net Calls
-$42.4M
Net Calls Change
-$147M
Name Holding Trade Value Shares
Change
Change in
Stake
X
276
Xponance
Pennsylvania
$6.46M -$286K -3,659 -4%
Corient Private Wealth
277
Corient Private Wealth
Florida
$6.45M +$546K +6,994 +9%
CIBC Asset Management
278
CIBC Asset Management
Ontario, Canada
$6.44M -$14.8K -190 -0.2%
AV
279
ASR Vermogensbeheer
Netherlands
$6.42M -$35.1K -449 -0.5%
VPIM
280
Vanguard Personalized Indexing Management
California
$6.4M -$53.4K -683 -0.8%
YCM
281
Yousif Capital Management
Michigan
$6.38M -$292K -3,741 -4%
OC
282
Oppenheimer & Co
New York
$6.36M +$558K +7,141 +10%
SCI
283
S&CO Inc
Massachusetts
$6.34M -$50.8K -650 -0.8%
CF
284
Covea Finance
France
$6.31M +$6.34M +81,101 New
CBU
285
CIBC Bancorp USA
Illinois
$6.3M +$6.33M +80,982 New
AAF
286
Andra AP-fonden
Sweden
$6.27M +$6.2M +79,400 +6,617%
RB
287
Rodgers Brothers
Pennsylvania
$6.27M
CCM
288
Cinctive Capital Management
New York
$6.06M -$6.12M -78,272 -50%
Public Employees Retirement Association of Colorado
289
Public Employees Retirement Association of Colorado
Colorado
$5.84M -$71.3K -912 -1%
FMI
290
Factory Mutual Insurance
Massachusetts
$5.84M
NAM
291
Nissay Asset Management
Japan
$5.82M +$58.5K +749 +1%
SMDAM
292
Sumitomo Mitsui DS Asset Management
Japan
$5.78M +$46.7K +598 +0.8%
SGA
293
Sector Gamma AS
Norway
$5.68M +$2.42M +30,980 +74%
Two Sigma Investments
294
Two Sigma Investments
New York
$5.61M +$1.39M +17,837 +33%
TCM
295
Telos Capital Management
California
$5.61M +$756K +9,670 +15%
JF
296
Jump Financial
Illinois
$5.58M +$5.61M +71,780 New
AF
297
Avanza Fonder
Sweden
$5.58M +$717K +9,173 +15%
TFGT
298
TS Financial Group (TSFG)
Illinois
$5.57M -$38.8K -496 -0.7%
Mackenzie Financial
299
Mackenzie Financial
Ontario, Canada
$5.52M +$812K +10,395 +17%
SRC
300
Stone Run Capital
New York
$5.48M -$3.91K -50 -0.1%

EW Hedge Fund Activity: Q3 2025 in Review

1,253 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q3 2025, worth a combined $38.2B — down 3% from $39.4B a quarter earlier.

Buyers outnumbered sellers: 113 funds opened new EW positions and 106 closed out — a net gain of 7 holders — while 444 added to existing stakes and 443 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $942M. The largest seller was Citadel Advisors, cutting an estimated $664M.

  • 1,253 institutional investors held Edwards Lifesciences (EW) as of Q3 2025, down from 1,259 in Q2 2025.
  • Funds reported $38.2B of Edwards Lifesciences stock for Q3 2025, down 3% quarter-over-quarter.
  • 113 funds opened new Edwards Lifesciences positions in Q3 2025 and 106 closed out, a net change of +7 holders.
  • The largest Edwards Lifesciences buyer in Q3 2025 was Fidelity Investments, an estimated $942M added.
  • The largest Edwards Lifesciences seller in Q3 2025 was Citadel Advisors, an estimated $664M sold.

Based on aggregated 13F filings for Q3 2025.